 WIXOM, Mich., Feb. 09, 2021 GLOBE NEWSWIRE -- Rockwell Medical, Inc. Nasdaq: RMTI, a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that Triferic AVNU ferric pyrophosphate citrate injection, the intravenous IV formulation of Triferic, is now available to patients in the United States. Triferic AVNU was approved by the U.S. Food and Drug Administration FDA in March 2020 and is indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease HDD-CKD. 